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Abstract
Background: The estrogen receptor a (ERa) is a ligand-regulated transcription factor. However, a wide variety of other
extracellular signals can activate ERa in the absence of estrogen. The impact of these alternate modes of activation on gene
expression profiles has not been characterized.
Methodology/Principal Findings: We show that estrogen, growth factors and cAMP elicit surprisingly distinct ERa-
dependent transcriptional responses in human MCF7 breast cancer cells. In response to growth factors and cAMP, ERa
primarily activates and represses genes, respectively. The combined treatments with the anti-estrogen tamoxifen and cAMP
or growth factors regulate yet other sets of genes. In many cases, tamoxifen is perverted to an agonist, potentially
mimicking what is happening in certain tamoxifen-resistant breast tumors and emphasizing the importance of the cellular
signaling environment. Using a computational analysis, we predicted that a Hox protein might be involved in mediating
such combinatorial effects, and then confirmed it experimentally. Although both tamoxifen and cAMP block the
proliferation of MCF7 cells, their combined application stimulates it, and this can be blocked with a dominant-negative Hox
mutant.
Conclusions/Significance: The activating signal dictates both target gene selection and regulation by ERa, and this has
consequences on global gene expression patterns that may be relevant to understanding the progression of ERa-
dependent carcinomas.
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Introduction
Inreproductive tissues, estrogens andpeptidegrowthfactors (GFs)
are mitogenic and play important roles in the normal and aberrant
development. The first indication that these signaling pathways
communicate with each other was the observation that serum,
insulin and IGF-I can stimulate ERa activity [1]. Indeed, ERa has
been shown to be activated as a transcription factor by many
signaling pathways even in the absence of its cognate ligand estrogen
([2]; and http://www.picard.ch/downloads/downloads.htm).
The biological cooperation between the EGF and IGF-I
receptor pathways and ERa is the best studied to date. Antibodies
against EGF inhibit estrogen-induced proliferation of uterine tissue
[3] and the ER antagonist ICI164,384 reduces the response to
EGF [4]. This relationship was confirmed genetically, since studies
with ERa knockout mice showed a requirement for ERa for EGF-
induced uterine growth [5,6]. Moreover, the estrogen-dependent
proliferation of the uterine stroma is defective in EGF receptor
knockout mice [7]. In cultured cells, IGF-I is able to stimulate the
transcriptional activity of ERa in the absence of hormone [8,9].
The estrogen-independent activation of ERa by EGF requires the
direct phosphorylation of ERa by MAPK [10] and this allows the
recruitment of both positive and negative coregulators [11].
Elevated levels of cAMP also activate ERa in a ligand-
independent fashion, but little is known about the mechanism of
this response [12,13]. Dopamine D1 receptor agonists like
dopamine, which lead to increased levels of cAMP and activation
of protein kinase A (PKA), have been shown to activate ERa in the
absence of hormone [14]. PKA has been shown to modulate ERa
function by phosphorylating the ERa residues S167, S236 and
S305 [15–18]. However, there is no evidence that the PKA-
elicited hormone-independent activation of ERa is a consequence
of direct phosphorylation [19], and we have recently found that
this activation is mediated by the phosphorylation-induced
interaction with a transcriptional coactivator (P.D. et al.,
unpublished results).
Although the role of estrogen signaling for breast cancer has
been extensively studied, it is not clear to what extent ligand-
independent activation of ERa contributes to breast cancer
progression to estrogen-independent or endocrine therapy-resis-
tant forms. Overexpression or activation of the EGF receptor
ErbB2 (also known as HER2 and Neu) or activation of MEKK1
has been shown to lead to resistance to the anti-estrogen tamoxifen
in cell culture ([20–22], see also ref. [23]). Inhibition of ErbB2 or
the p42/44 MAP kinases Erk1/2 restored the inhibitory effects of
tamoxifen, underlining the importance of the MAPK pathway in
PLoS ONE | www.plosone.org 1 March 2008 | Volume 3 | Issue 3 | e1859regulating cellular growth in these systems [24]. Indeed, in clinical
samples, Erk1/2 have been observed to be hyperactive and
overexpressed in malignant breast tumors [25] and their activity
correlates with a poor response to endocrine therapy and
decreased survival of patients [26]. Furthermore, breast tumor-
derived cells that exhibit elevated MAPK expression are
hypersensitive to estradiol [27]. Interestingly, the ER coactivator
SRC3 is amplified in breast and ovarian cancers [28], and is itself
a target of the p42/44 MAPK pathway [29]. In a retrospective
clinical study on tamoxifen treatment, co-overexpression of SRC3
with ErbB2 was correlated with the poorest outcomes in patients
treated with tamoxifen [30].
The cAMP/PKA pathway may also contribute to endocrine
resistance. Indeed, higher levels of cAMP-binding proteins were
isolated from breast tumor samples that were resistant to
endocrine therapy, compared with those that were not, suggesting
the presence of a very active cAMP/PKA pathway [31]. A gene
profiling study showed that the expression of one of the regulatory
subunits of PKA, RIa, is significantly reduced in primary breast
tumor samples and correlates with tamoxifen insensitivity [32].
This may be due to a hyperactive PKA phosphorylating ERa on
S305 and locking it into a different conformation in the presence
of tamoxifen [17,18].
A considerable number of studies have been published that used
DNA microarray technology to characterize the gene expression
responses of breast cancer cells to estrogens and anti-estrogens (for
example, refs. [33–38]). Except for one study that compared the
GF responses of the uterus of ERa knock-out and wild-type mice
[39], the impact of ligand-independent activation of ERa has not
been investigated at the genomic level. We used microarray
technology to determine whether different modes of activation of
ERa lead to similar or different genomic responses and how those
are affected by tamoxifen in human MCF7 breast cancer cells. We
then performed a computational analysis on a set of target genes to
predict the involvement of additional transcription factors and
experimentally confirmed that some are responsible for the
proliferative stimulus of the combined treatment of MCF7 cells
with cAMP and tamoxifen.
Results
Genomic estrogen, cAMP and GF responses
Recent studies concluded that the ERa-positive human breast
carcinoma cell line MCF7 is an excellent model system for gene
expression studies since the gene expression profiles are nearly
identical to ERa-positive breast tumor xenografts and primary
tumors [37]. Here we analyzed signaling crosstalk-specific profiles
with MCF7 cells using a human cDNA array. To ensure that the
expression profiles would be due to primary transcriptional
responses, cells were induced for only 4 hours and in the presence
of the translation inhibitor cycloheximide. Details on the
experimental design and methodology are given in Supporting
Information Text S1, and the treatments are listed and illustrated
in Supporting Information Table S1 and Figure S1A, respectively.
220 unique transcripts of the 9,480 represented on the cDNA
arrays responded to at least one of the three treatments by at least
2-fold (Figure 1A and Supporting Information Table S2). The
genes regulated in the sample treated with 17b-estradiol (E2)
accounted for 90 (40.9%) of all regulated genes, including many
genes known to be regulated by E2 such as PGR (progesterone
receptor gene), BCL2, FOS and GREB1. Other genes known to
respond to estrogens like the Cyclin D1 gene (1.6-fold, p=0.007)
and TFF2 (1.38 fold, p=0.03), also responded to E2 in our
experiment, albeit more weakly. The cAMP-regulated target genes
Figure 1. Analysis of gene expression profiles in response to different signals. (A) Venn diagrams of gene sets regulated by E2/GFs/cAMP.
Top and bottom panels: genes regulated by at least 2-fold (total of 220 genes) and 1.5-fold (922 genes), respectively. (B) Hierarchical clustering
analysis with Eisen tree of 2-fold gene set. (C) Clustering analysis using the gene sets defined separately by a 1.5-fold cut-off for each treatment. Green
and red colour bars represent repression and induction, respectively, compared to control (untreated). Black bars indicate no change.
doi:10.1371/journal.pone.0001859.g001
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genes. The known cAMP-responsive genes encoding p27/Kip1
(1.54 fold, p=0.009) and Atf3 (1.65 fold, p=0.012) also scored
positive albeit below the 2-fold cut-off. The GF-treated sample
showed the highest differential expression patterns compared with
the control, accounting for 59.1% (130 of 220) of all genes
regulated at least 2-fold, and the largest proportion of genes
regulated at least 1.5 fold (623 of 922, or 67.6%). Classical EGF
and IGF-I regulated genes such as FOS and ERBB3 showed strong
responses to the GF cocktail. Figure 1B represents a hierarchical
clustering analysis and Eisen tree of the responses of the 220 genes
that exhibited expression differences of at least 2-fold in the E2,
cAMP and EGF/IGF-I treated samples. Figure 1C represents
three clustering analyses of the genes affected at least 1.5-fold by
each treatment: E2 (360 genes), EGF/IGF-I (623 genes) and
cAMP (122 genes), with a total of 922 unique transcripts.
Validation of some microarray results by quantitative
real-time RT-PCR
In order to verify the gene expression patterns observed in the
microarray analysis, several genes with diverse patterns were
selected and confirmed by Q-PCR. We chose two genes known to
be regulated by E2 (BCL2 and TFF1/pS2), and several others with
interesting expression patterns and potential relevance to cell
proliferation and cancer, including RGS16 (Regulator of G protein
signaling 16), RAP1GAP (Rap1 GTPase activating protein 1),
CCNG2 (Cyclin G2) and EPHB3 (Ephrin type-B receptor 3 precursor).
As an internal control, DMN3 (Dynamin 3) was selected because of
its abundant expression in all samples and the absence of
detectable differences in expression under all treatment conditions.
The results from three conditions (E2, GFs, and cAMP) are shown
in Figure 2 along with a dendrogram representing the microarray
data for comparison. Although in some cases the quantitative
expression values from the PCR results differed considerably from
the microarray data, the results are qualitatively identical. Thus,
the Q-PCR results validated the gene expression patterns of the
genes tested.
ERa-dependent gene regulation via crosstalk with cAMP
and GFs
Having established that a subset of genes is regulated
independently by several treatments, we determined for which of
the genes the regulation by cAMP or EGF/IGF-I is ERa-
dependent. ERa-signaling can be blocked with the pure anti-
estrogen ICI 182,780 (ICI), and therefore combining it with cAMP
or EGF/IGF-I should specifically affect ERa-dependent genes,
including those regulated by cAMP or GFs. We quantitatively
defined an ERa-dependent gene as one for which the difference of
expression with the addition of ICI was at least 20%. E2+ICI and
E2+hydroxytamoxifen (OHT) treatment controls were deliberate-
ly not included since these kinds of data already abound in the
literature, and since the focus of our study was on signaling
crosstalk and not on (re-)identifying genes regulated by E2- or
OHT-activated ERa. It must be emphasized that ICI does not act
as an antagonist for the novel membrane-associated estrogen
receptor GPR30 [40–42] allowing us to use this pharmacological
criterion to define ERa-dependence.
In total, 65 of 623 (10.4%) GF-regulated genes were affected by
ICI treatment (Figure 3A top and 3B left; Supporting Information
Table S3). The genes appear to organize into 8 unique clusters,
labelled I–VIII. Cluster I represents genes that are independently
induced by E2 and GFs and repressed by ICI alone. Repression by
the sole treatment with ICI suggests that these are genes with a
strong ERa basal activity. Cluster II differs from I by the fact there
is no difference in the ICI-only sample and hence no basal ERa
activity. The behavior of the genes in cluster III is similar to those
of cluster I, differing only in the absolute expression values. Cluster
IV represents genes that, by and large, are not significantly
induced by E2 (if at all), unaffected in the ICI-only sample but
induced by GFs in an ERa-dependent fashion. Cluster V
Figure 2. Verification of microarray data by Q-PCR. Top panel: dendrogram of fold expression ratios from the microarray data of the genes
DNM3, BCL3, RGS16, TFF1 (pS2), RAP1GAP, EPHB3 and CCNG2. Yellow and cyan indicate induction and repression, respectively. Bottom panel: Q-PCR
results for three conditions (E2, GFs and cAMP). Log-scale graph of the fold expression values calculated with the DDCt method using DNM3 as
internal control. Values shown are the means of triplicate samples 6 standard deviation.
doi:10.1371/journal.pone.0001859.g002
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treatment, i.e. the genes with the strongest dependence on ERa for
induction. In contrast to clusters I–V, clusters VI–VIII collectively
correspond to genes that are repressed by GF treatment and
derepressed by ICI. Cluster VI includes genes with a significant
difference in the ICI-only sample, whereas cluster VII does not.
However, both VI and VII contain genes that are repressed by E2.
Cluster VIII resembles IV in that neither E2 nor ICI-alone affects
expression. Clusters IV and VIII are examples of genes that are
regulated by ERa exclusively upon activation by GFs and not by
E2.
With the original more stringent 2-fold cut-off, the set of cAMP-
regulated genes was relatively small. We therefore lowered the
threshold to 1.3-fold to obtain a larger number of ERa-dependent
genes (Figure 3A bottom and 3B right; Supporting Information
Table S3). Of the 28 genes, 26 could be classified into three unique
clusters. The two remaining genes, LMCD1 and RAFTLIN,
exhibited their own unique behaviors. All three clusters exhibited
no significant changes in expression in the ICI-only sample.
Cluster I is the largest of the classes, accounting for half of the
genes in this set, and representing genes that are repressed by
cAMP in an ERa-dependent way but not affected by E2. Much
like for clusters IV and VIII from the GF gene set, ERa appears to
be required but not sufficient to regulate these genes, at least in the
presence of E2. Cluster II represents genes that are repressed by
both E2 and cAMP. In contrast, cluster III corresponds to genes
that are induced by both E2 and cAMP. The gene RAFTLIN
(double asterisk) is the only example of a gene for which E2 had no
effect and yet cAMP induced it in a partially ERa-dependent
fashion. The gene LMCD1 (single asterisk) is the only one in either
ERa-dependent gene set to exhibit opposite responses to hormone
and to signaling crosstalk.
Effects of cAMP and GFs on the tamoxifen response
Unlike ICI, OHT is not a pure anti-estrogen and can even
activate ERa in a context-dependent manner. Thus, in addition to
studying the genomic effects of ligand-independent activation of
ERa, we wished to understand how signaling crosstalk can
influence the intrinsic agonistic or antagonistic activities of OHT
at the genomic level. We defined an OHT-coregulated gene (as
opposed to a gene that is affected by OHT alone) as one where
OHT-cotreatment resulted in an expression difference of at least
1.3-fold compared to cAMP/GFs alone. However, if a gene
exhibited the same behavior in the OHT-alone sample as in the
cotreatment sample, then it was filtered out and not further
considered in the analysis. In addition, in order not to confuse, for
instance, inverse agonism with antagonism, the cotreatment
sample genes were filtered out if they behaved in the opposite
fashion in the presence of E2. This was the case, for example, for
genes that are repressed by E2 but induced by the addition of both
OHT and cAMP or GF. Although we cannot formally exclude the
possibility that some OHT (or E2) signaling effects in MCF7 cells
were mediated by ERa-independent pathways such as those
regulated by GPR30, the focus on genes differentially affected by
the combined treatments of OHT with cAMP or GFs (based on
the ‘‘filtering’’ mentioned above) would tend to exclude a major
contribution of those. Moreover, preliminary results from profiling
GPR30-mediated gene expression changes in response to OHT
indicate an entirely different set of target genes than the ones
studied here (Deo Prakash Pandey, Marcello Maggiolini, and DP,
unpublished results).
OHT was found to coregulate 80 genes in concert with cAMP
compared to only 28 genes with GFs (Supporting Information
Table S4, and Figure 4B). This was an unexpected finding
considering the proportion of genes that cAMP and GFs regulate
Figure 3. Ligand-independent ERa-mediated gene expression profiles. (A) Log expression ratios of the ICI-affected GF-regulated (65 genes)
and cAMP regulated (28 genes) gene sets at the top and bottom, respectively. (B) Hierarchical cluster analysis with Eisen tree of gene sets shown in
panel A. Interesting clusters are numbered on the right. Asterisks denote genes with unique response that are discussed in the text. Colour code as in
Figure 1.
doi:10.1371/journal.pone.0001859.g003
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significantly more effective than GFs at modulating OHT activity.
A cluster analysis of these genes is shown in Figure 4A. To
highlight the importance of filtering out those genes that display
the same behavior with OHT alone, this analysis, as an exception,
still includes them. There is remarkably little overlap between the
responses to these different treatments (Figure 4B), illustrating a
crosstalk-specific agonistic activity for OHT that differs substan-
tially from its intrinsic agonistic activity. It should be noted that the
term agonist is used here to denote a ligand, OHT, that turns on
ERa activity above its basal activity, irrespective of whether it then
acts as a repressor or an activator of transcription. Genes where
OHT showed the strongest agonistic activity are illustrated in
Figure 4C, and are shown separately for both crosstalk signals.
Interestingly, there was a small group of genes in the original set of
108 OHT-coregulated genes (80 coregulated with cAMP plus 28
coregulated with GFs) that exhibited the intriguing behavior of
opposing responses when comparing the two crosstalk signals
(Figure 4C). Whereas OHT induces the expression of HSPB8,
GREB1 and CXCL12 in the cAMP-treated sample, it represses it in
the GF-treated sample. Similarly, OHT derepresses the GF-
induced repression of HSPC051, whereas it represses the same
gene in the cAMP-treated sample. Since these opposing behaviors
occur with the same genes, it implies that there are two
independent molecular mechanisms of OHT-mediated signaling
crosstalk.
Computational analysis of promoters involved in ERa-
dependent, cAMP-regulated gene regulation
The ligand-independent activation of ERa by cAMP leads to
the regulation of a distinct set of genes (Figure 3B, right panel)
whose responses to various other treatments are highlighted in
Figure 5 (top panel). We hypothesized that the regulation of the
ERa-dependent/cAMP-regulated genes might be explained by a
simple combinatorial code of transcription factor co-recruitment
that could be detected by analyzing the promoter/enhancer
regions of these genes. To facilitate the computational promoter
analysis, we employed ModelInspector [43], a component of the
GenomatixSuite software. Of the 28 unique transcripts that were
cAMP-regulated and affected by ICI treatment (ERa-dependent)
in our microarray data set, 21 were identifiable genes whose
promoter sequences could be downloaded and analyzed. These
sequences were scanned with ModelInspector for matches to a
predefined library of functional promoter modules. A ‘‘module’’ is
defined by a combination of two to three specific transcription
factor binding sites, their order, strand orientation and distance
Figure 4. Interplay between OHT and signaling crosstalk. (A) Hierarchical cluster analysis with Eisen tree of genes affected by OHT in GF- and
cAMP-treated samples. Gene set includes 20 genes that also respond in the same manner to OHT alone (marked with dotted lines). Some sets of
genes with interesting behaviors are marked with solid lines and listed. (B) Venn diagrams illustrating overlap between gene sets obtained with OHT
alone or in combination with cAMP or GFs. (C) Selected patterns of genes most strongly affected by the agonistic activity of OHT. Arrows mark rows
of most relevant pairwise comparisons.
doi:10.1371/journal.pone.0001859.g004
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factor binding sites (modules) are illustrated in Figure 5. Most
importantly, no single 2-element or 3-element module was found
to occur in all promoters from either the upregulated or repressed
group of genes. The top three 3-element modules in the cAMP-
induced group (MI1, MI2 and MI3) occurred in 3 out of 6 of
promoters, but 5 out of 6 promoters were covered by a
combination of MI1 and MI3. Only the MITF promoter
contained all three modules. In the cAMP-repressed group, fewer
common 3-element modules were uncovered than in the cAMP-
induced group (3 versus 8), despite there being significantly more
promoters to scan; this may reflect a more robust functional
conservation of the respective promoters. The MR2 and MR3
modules were found in 5 out of 15 promoters each, whereas the
MR1 module occurs in 8 promoters, though two of those
promoters, belonging to the ID1 and ARF4L genes, contain a
poorly conserved MYT1 site (marked with dotted lines in Figure 5).
There is significant overlap among the 3 modules, and yet, one
third of the promoters in this group had no detectable 3-element
module. Results from a genome-wide search of these modules in
Figure 5. Computational modelling of transcription factor binding site modules in ERa-dependent/cAMP-regulated promoters. Top
panel: microarray data of those genes from this set for which promoter sequences (21000 bp to +100 bp) were available (21 out of 28). Middle panel:
list of ten highest scoring 2-element transcription factor binding site (2xTFBS) modules. Bottom panel: list of three optimized modules containing 3
transcription factor binding-sites (3xTFBS) each; hashed lines, partial module coverage; grey boxes, conserved 2xTFBS module transmitted to a
3xTFBS module; black box, conserved 1xTFBS transmitted to a 3xTFBS module; asterisks denote genes with no detectable 3xTFBS modules. + and 2
indicate strand orientation, and digits indicate distances in base pairs between transcription factor elements.
doi:10.1371/journal.pone.0001859.g005
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summarized in Supporting Information Tables S5-B and S5-C.
Requirement for a homeodomain-containing protein for
cAMP/OHT-dependent proliferation of MCF7 cells
Much like anti-estrogens such as OHT, cAMP is known to
inhibit E2-dependent proliferation of MCF7 cells by inhibiting the
G1/S transition [44–46] (see also Figure 6A). Remarkably, the
antiproliferative activity of cAMP is partially rescued with OHT
(Figure 6A), which may be due to cAMP-induced OHT-agonism.
Intriguingly, about half of the genes (11 out of 21) used in the
promoter analysis of ERa target genes regulated by cAMP are also
genes whose expression was subject to cAMP-induced OHT-
agonism (Figure 6B). Therefore, we hypothesized that one or more
of the transcription factor binding site modules found earlier might
be involved, in conjunction with ERa, in the transcriptional
regulation of a gene (or genes) important for proliferation induced
by the combined treatment with cAMP and OHT.
To test this, we overexpressed dominant-negative (dn) forms of
Hox, Pax5, and CREB in MCF7 cells (representing the modules
MI1, MI2 and MR1, respectively), and measured the proliferative
responses to OHT and cAMP (Figure 6C). Neither overexpression
of dnPax5 nor dnCREB blocked cAMP/OHT-induced prolifer-
ation. dnCREB even slightly promoted proliferation, possibly
because CREB is the target and mediator of the anti-proliferative
cAMP pathway. In contrast, overexpression of dnHox significantly
inhibited cAMP/OHT-induced proliferation whereas it had no
effect on E2-induced proliferation. dnHox was derived from
HoxD13, but since it essentially only contains the homeodomain,
we expect it to function as a dominant-negative mutant for many
homeodomain-containing transcription factors. Thus, these results
suggest that an as yet unidentified homeodomain-containing
Figure 6. A Hox protein mediates cAMP-induced agonistic switch of OHT for MCF7 proliferation. (A) MCF7 proliferation assay. Equal
numbers of cells (2610
5) were seeded onto plates and then treated over a period of 6 days with vehicle control (0.1% ethanol), 10 nM E2, 1 mM 8-Br-
cAMP (cAMP), 1 mM OHT or combinations thereof. (B) Venn diagram showing overlap between the cAMP-regulated/ERa-dependent genes and genes
OHT-regulated by cAMP (corrected for E2 and OHT behavior as described in the text). The overlapping 14 genes include the 11 genes used in the
promoter analysis of Figure 5 (ARF4L, ARFIP1, CLPS, DPP6, GRIA3, KLK1, NDUFB2, P2RY13, RAFTLIN, RAG2, UBCE7IP5) and the unannotated transcripts/
genes KIAA0406, KIAA0556 and Hs.541338 (see Supporting Information Tables S3 and S4). (C) Effect of dominant-negative transcription factor
mutants on proliferation of MCF7 cells. Cells were transfected with expression vectors for dnPax5, dnCREB or dnHox, or empty expression vector
(control). Data in panels A and C are representative of two independent experiments.
doi:10.1371/journal.pone.0001859.g006
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proliferation of MCF7 cells.
Discussion
The key finding of our comparative microarray analysis is that
cAMP, growth factors and estrogen elicit vastly different
transcriptional responses, both at the level of the whole genome
and, perhaps more remarkably, of ERa-dependent genes. Thus,
depending on how ERa is activated, it regulates largely different
sets of genes. Another unexpected finding is that ERa primarily
represses genes in response to cAMP despite the fact that this
particular response was originally characterized with a reporter
gene that monitors activation. Although a large number of
microarray studies that focused on ERa and/or breast cancer cells
had been reported (for example, refs. [33–39]), these aspects had
been missed. Our analysis uniquely concentrated on signaling
crosstalk with ERa, notably its ligand-independent activation, and
on the agonistic effects of OHT in the presence of additional
extracellular signals, which at least in part are also mediated by
ERa.
ERa-dependent gene expression and signaling crosstalk
Among the ERa-dependent groups of genes with varied
behavior, clusters IV and VIII from the GF sample and cluster I
from the cAMP sample are extremely interesting. They represent
genes whose regulation by GFs or cAMP requires ERa, but for
which the cognate ligand E2 has no effect. This is strong evidence
that cAMP and GFs are activating ERa in a ligand-independent
manner. Moreover, it argues that ligand-independent activation
can lead to a specific gene expression response, which differs
markedly from the hormone-dependent response. The ligand-
independent response also varies depending on the source of the
signal, since there is virtually no overlap between the ERa-
dependent genes regulated by cAMP and those regulated by GFs.
Indeed, to our surprise, among the 96 unique transcripts that were
ERa-dependent in the crosstalk samples, only one gene,
TFF1(pS2), appeared in both the cAMP and GF group (see also
top panel in Figure 5). This supports the idea that cAMP and GF-
signaling lead to different ERa-dependent outcomes, and suggests
that two distinct ligand-independent mechanisms of activation are
at play.
Moreover, there are interesting differences between the two
signaling crosstalk responses. For instance, there is not a single
example of an ICI-affected gene that is repressed by E2 and
induced by GFs (or vice versa). When E2/GF-regulation requires
ERa, it appears to be always unidirectional. This does not seem to
be the case with E2/cAMP regulation. LMCD1, for instance, is
weakly induced with E2 alone, but repressed by cAMP, and yet,
both responses require ERa. Another difference between the two
ligand-independent responses is the relative distribution of
induction and repression of gene expression. Whereas GFs
activate ERa primarily to induce gene expression, it appears that
cAMP activates ERa to repress the expression of genes.
Unfortunately, still relatively little is known about how E2-
liganded ERa represses genes [47-49]. Hence, it is difficult to
begin to speculate about the molecular mechanisms.
A first indication about the underlying molecular mechanisms
that direct signal-specific responses comes from a recent study by
Surmacz and colleagues [50]. Using chromatin immunoprecipi-
tation experiments, they found that different coactivator complex-
es are assembled on two selected ERa target genes in response to
E2 or IGF-I. The nature of these complexes was both signal-
dependent and influenced by whether ERa was recruited to the
target gene directly through an estrogen response element or
indirectly through another transcription factor (AP1). Taken
together with our own genomic analysis, this argues that different
signals activate ERa to do different things, either on different
genes or even on the same gene. At the molecular level, this means
that ERa assembles different coactivator (or corepressor) com-
plexes as a function of target gene and activating signal. It is also
conceivable that different signals already direct ERa to different
target genes. Future experiments will address these mechanistic
aspects as well as the physiological consequences of these signal-
specific responses.
Our findings seem to contradict those found by the only other
microarray study that specifically looked at ERa/GF signaling
crosstalk, and which concluded that the GF response is not altered
by the deletion of the ERa gene in the mouse [39]. While it was
difficult for these authors to reconcile these results with their
previous demonstration that the growth response of the uterus to
GFs is mediated by ERa [5,6], it has not been clarified whether
estrogen and GFs both crosstalk and act in parallel in this system
and to what extent these are responses specific to the uterus.
Agonistic activity of tamoxifen and implications for
endocrine resistance
Our findings may also have implications for endocrine therapy.
A large proportion of ER+ breast cancers eventually become
resistant to anti-hormone treatment [51]. There is also a large
body of evidence that directly implicates the aberrant behavior of
growth factor receptor pathways, in particular the ErbB2 and
MAPK pathways, in the acquisition and maintenance of
tamoxifen resistance (discussed in ref. [2]). Furthermore, very
few studies have been done on the role of cAMP signaling for anti-
hormone resistance, despite first evidence as early as 1990 [31].
Although cAMP/PKA signaling has been shown to pervert
tamoxifen to an agonist for ERa target gene activation [17,52],
the molecular mechanisms remain unclear. Nevertheless, our
analysis further illustrates that studying the effects of OHT on gene
transcription in isolation may not yield an accurate picture of its
biological activity in vivo and highlights the importance of
considering the cellular signaling environment as a whole when
interpreting such results.
The computational analysis of signal-specific ERa target gene
sets did not reveal a single common transcription factor framework
that could reliably explain or predict the observed genetic
behavior. This may indicate a multi-layered complexity that
would require further experimentation to separate. Despite this,
several highly specific promoter modules containing three
transcription factor binding sites separated by a specific distance
with a specific strand orientation were found in ERa target genes
differentially regulated by cAMP. Three modules were revealed
that contain highly conserved Hox, Pax5 and CREB transcription
factor binding sites. We addressed the physiological significance of
this in silico association with a MCF7 proliferation assay. It was
known that elevation of cAMP suppresses E2-dependent prolifer-
ation of MCF7 cells [44–46], but not of tamoxifen-resistant
MCF7-LCC2 cells [46]. We observed that cAMP in combination
with OHT promotes the proliferation of MCF7 cells, albeit at
less than 50% the effectiveness of estrogen. This is the first time
that the potentially adverse consequences of cAMP signaling
crosstalk for endocrine therapy are recapitulated by augmenting
cAMP levels in tissue culture, and not just for the activation of
one or two ERa target genes. It confirms a previous report that
showed a similar growth stimulation by knocking down expression
of a regulatory subunit of PKA [17]. Furthermore, overexpression
of a dominant-negative Hox protein, harboring only the
ERa Crosstalk Genomics
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proliferation. This result implicates a homedomain-containing
transcription factor as a transcriptional facilitator of OHT-agonism.
By ‘‘facilitator’’ we mean that the Hox protein(s) could be required to
allow the regulation of genes required for proliferation by ERa in the
presence of cAMP and OHT. This does not need to involve any kind
of direct interaction between a Hox protein and ERa,b u ti n s t e a dt h e
Hox protein might merely prepare a promoter or enhancer for
regulation by ERa. Although the computational analysis strongly
suggests some kind of functional interaction, it is formally conceivable
that a Hox protein acts through an unrelated (ERa-independent) gene
i nt h ep r e s e n c eo fc A M Pt os y n e r g i ze with OHT. Such mechanistic
questions will be addressed most efficiently once the Hox protein(s)
will have been identified. It will also be interesting to evaluate whether
a direct phosphorylation of this Hox protein(s) by PKA, as is known
for the paradigmatic PKA-regulated transcription factor CREB [53],
contributes an additional layer of regulatory complexity.
Hox proteins are a large family of transcription factors. The most
common element among all factors is the highly conserved
homeodomain, which is a 61 amino acid helix-turn-helix DNA
binding motif. In addition, over 100 other human proteins contain
the homeodomain as well. HOX genes are important in embryo-
genesis and organogenesis because they regulate cell proliferation
and differentiation. Since normal development and cancer involve a
balance between proliferation and differentiation, it is not surprising
that HOX genes have been linked to many different tumors,
including breast cancer [54]. Expression studies of the entire HOX
gene cluster in breast cancers revealed elevated expression for
several members, including HOXA4, B3, B13, C13, D3 and D13.
Moreover, HOXB13 overexpression can be used as a component of
a two-gene signature predicting poor outcome in tamoxifen-treated
patients,anditsectopicexpression promotes motilityand invasion in
vitro [55]. It remains to be determined which Hox protein is the one
that is required for the proliferation of breast cancer cells exposed to
both tamoxifen and signals elevating cAMP.
Our analysis provides a genomic glimpse into how cAMP and
GFs pervert tamoxifen into an agonist, and sets the stage for
identifying and characterizing genes involved in causing resistance
to endocrine therapy. It will also have to be established what the
source of signals may be that leads to elevated levels of cAMP and
GFs. Apart from autocrine or paracrine signals from the epithelial
cells themselves, a stromal origin should be considered. The recent
discovery that mesenchymal cells promote the metastasis of breast
cancer cells is a telling illustration [56]. At least for a subset of
ERa-dependent carcinomas, our genomic analyses emphasize the
necessity to consider the impact of additional extracellular signals
on the effectiveness of tamoxifen as an antagonist. Our results
might ultimately facilitate the development of personalized forms
of endocrine therapy.
Materials and Methods
Cell culture
An estrogen-independent (but not ERa-independent) MCF7
variant MCF7-SH [57] was used for microarray and Q-PCR
experiments. Because this MCF7 variant expresses higher levels of
ERa, transcriptional responses could be expected to be more
robust. These cells were grown in phenol red-free Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10% (v/v)
charcoal-treated fetal calf serum (FCS). For proliferation assays,
estrogen-dependent MCF7 cells (a gift from F. Auricchio, Naples)
had to be used. They were maintained in medium supplemented
with E2. Note that both of these types of MCF7 cells express ERa
but not ERb (data not shown).
Microarray analysis
The human 10K E cDNA arrays, generated by the DNA Array
Facility of the University of Lausanne, Switzerland (DAFL), are based
on the Incyte cDNA collection (for details, see GEO accession number
GPL2746). Treatments for expression analyses were for 4 hours with
100 nM 17b-estradiol (E2), hydroxytamoxifen (OHT) or ICI182,780
(ICI), 1 mM 8-Br-cAMP or a combination of 50 mg/ml EGF and
50 mg/ml IGF-I, in the presence of cycloheximide. The detailed
procedures for treating the cells, isolation of RNA, and production of
Cy5- and Cy3-labelled cDNA probes of treatment and control
samples, respectively, are described in Supporting Information Text
S1 and Figures S1 and S2. Cluster analysis was done using the software
Genespring (Agilent), and promoter analysis was done with the
GenomatixSuite software (www.genomatix.de), notably ModelInspec-
tor and the proprietary Promoter Module Library. The microarray
data were deposited with GEO (accession number GSE10466).
Quantitative real-time PCR analysis
Real-time RT-PCR was done as described in Supporting
Information Text S1 with the same total RNA sample replicates
used in the microarray experiments. Primers are listed in
Supporting Information Table S6.
Dominant negative constructs, MCF7 transfection and
proliferation assay
The expression vector pKW-prd-en for dominant negative Pax5
was a gift from M. Busslinger [58]. The plasmid for A-CREB was
a gift from C. Vinson [59]. A construct with exon 2 of HoxD13 in
Bluescript (a gift from D. Duboule) served as template for PCR
amplification of the homeodomain coding sequences with the
primers 59-GGGAATTCTGGATGTGGCTTTAAA-39 and 59-
GGAATTCTCAGGAGACAGTGTCTTTG-39. This PCR
product was cloned into EcoRI-BamHI-digested plasmid CKF
[60]. Estrogen-dependent MCF7 cells were seeded into 6-well
plates at 2610
5 cells per well in phenol red-free DMEM
supplemented with 5% (v/v) charcoal-treated FCS and transfected
using TransIT LT1 (Mirus) (day 0). Note that transfection
efficiencies routinely reached 70–90%. 24 hours post-transfection
(day 1), cultures were supplemented with hormones as required.
Cells were counted on days 2, 4, and 6.
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